Teva Pharma (TEVA) to Acquire Allergan Genetics (AGN) in $40.5B Cash and Stock Deal

Canaccord Genuity Raises Price Target on Teva Pharma (TEVA) Following Announced Acquisition of Allergan Generics

July 28, 2015 9:23 AM EDT

Canaccord Genuity maintained a Hold rating on Teva Pharma (NYSE: TEVA), and raised the price target to $79.00 (from $63.00), following the announced acquisition of Allergan Generics for $40.5B - $33.75B in cash and $6.75B in stock. Analyst Corey Davis said that this is not a good signal about the overall future of the... More

Canaccord Genuity Raises Price Target on Allergan (AGN) Following Announced Generics Sale

July 28, 2015 9:13 AM EDT

Canaccord Genuity reiterated a Buy rating on Allergen (NYSE: AGN), and raised the price target to $396.00 (from $352.00), following the announced sale of its generics unit to Teva (NYSE: TEVA). Teva will acquire the unit for $40.5B.... More

Leerink Partners Raised Price Target on Allergan (AGN) to $388 Following TEVA Announcement

July 28, 2015 8:19 AM EDT

Allergan (NYSE: AGN)
Leerink Partners reiterated an Outperform rating on Allergen (NYSE: AGN), and raised the price target to $388.00 (from $354.00), following this morning's announcement that TEVA will be acquiring AGNs Gx biz for $40.5B. Analyst Jason Gerberry views TEVA (OP) as the most suitable owner for the AGN's Gx assets.

Gerberry... More

Leerink Partners Raises Price Target to $84 on Teva Pharma (TEVA) Following Call with CFO

July 28, 2015 8:12 AM EDT

Leerink Partners reiterated an Outperform rating on Teva Pharma (NYSE: TEVA), and raised the price target to $84.00 (from $74.00), following a call with CFO Eyal Desheh. The TEVA-AGN deal is estimated to close in 1Q'16 and management still anticipates holding its annual guidance... More

Teva Pharma (TEVA) PT Bumped to $75 at Piper Jaffray

July 28, 2015 7:39 AM EDT

Piper Jaffray analyst David Amsellem lifted his price target on Teva Pharma (NYSE: TEVA) to $75.00 (from $57.00) on plans to acquire Allergan's generic business but maintained a Neutral rating.

Amsellem commented, "With Teva deadset on doubling down on its global exposure to... More

BMO Capital Starts Teva Pharma (TEVA) at Outperform

July 28, 2015 7:07 AM EDT

BMO Capital initiates coverage on Teva Pharma (NYSE: TEVA) with a Outperform rating and a price target of $80.00.

For an analyst ratings summary and ratings history on Teva Pharma click here. For more ratings news on Teva Pharma click here.

Shares of Teva Pharma closed at $72.00 yesterday.

... More

Allergen (AGN) PT Raised to $366 at UBS Following Generic Deal

July 28, 2015 6:57 AM EDT

UBS analyst Marc Goodman reiterated a Buy rating and boosted his price target on Allergen (NYSE: AGN) to $366.00 (from $333.00) after agreeing to sell its legacy generic business to Teva.

Commenting on takeaways from the conference call, the analyst highlighted:

(1) Allergan will divest the... More

Teva's (TEVA) Deal for Allergan Generics Seen as Positive at Deutsche Bank, PT Raised to $82

July 27, 2015 2:29 PM EDT

Deutsche Bank maintained a Buy rating on Teva Pharma (NYSE: TEVA) and raised its price target to $82.00 (from $73.00). Analyst Gregg Gilbert said he likes its acquisition of Allergan Generics and noted "significant operational synergies."

"The addition of Allergans strong generics business and best-in-class pipeline, coupled with the potential for significant operational synergies, makes AG an ideal... More

Teva Pharma (TEVA) PT Raised to $74 at Maxim Group on Deal for Allergan's Generic Drug Business

July 27, 2015 11:10 AM EDT

Maxim Group analyst Jason Kolbert reiterated a Buy rating and raised his price target on Teva Pharma (NYSE: TEVA) to $74.00 (from $64.00) after the company agreed to acquire Allergan's legacy Actavis global generics business. The company is dropping its bid for... More

Perrigo (PRGO) Gains After Teva (TEVA) Withdraws Proposal to Acquire Mylan (MYL)

July 27, 2015 7:25 AM EDT

Perrigo (NYSE: PRGO) gained after Teva Pharma (NYSE: TEVA) withdrew its proposal to acquire Mylan (NASDAQ: MYL). Tevas decision follows an announcement that Teva has entered into a definitive agreement with Allergan (NYSE:... More

Teva Pharma (TEVA) Prelim. Q2 Revenue, EPS Outpace Views

July 27, 2015 6:14 AM EDT

Teva Pharma (NYSE: TEVA) announced preliminary financial results for the second quarter of 2015:

Revenues of approximately $4.97 billion, down 2% compared to the second quarter of 2014. Excluding the impact of foreign exchange fluctuations and the sale of U.S. OTC plants in July 2014, revenues increased 6% compared to the second quarter of 2014.Non-GAAP diluted earnings per share (EPS) of $1.43 in the second quarter of 2015, up 15% compared to the second quarter of 2014.Non-GAAP operating income of $1.6 billion, an increase of 16%... More

Teva Pharma (TEVA) Ends Effort to Acquire Mylan (MYL)

July 27, 2015 6:07 AM EDT

Teva Pharma (NYSE: TEVA) announced that it has withdrawn its cash and stock proposal to acquire all of the outstanding ordinary shares of Mylan N.V. (Nasdaq: MYL) and Teva does not intend to continue to pursue a transaction with Mylan at this time. Tevas decision to terminate the proposal to acquire Mylan follows todays announcement that Teva has entered into a definitive agreement with Allergan to acquire Allergan Generics.

In... More

Teva Pharma (TEVA) Nears Deal to Acquire Allergan's (AGN) Generic-Drug Business

July 26, 2015 5:23 PM EDT

Israel-based drug maker Teva Pharma (NYSE: TEVA) is in talks to acquire Allergan's (NYSE: AGN) generic-drug business, the Wall Street Journal reported on Saturday. The deal is said to be valued at about $45 billion and could be announced as soon as Monday.

If a deal is... More

Consumer Reports Negative on Teva Pharma (TEVA), Mylan (MYL) Deal

July 24, 2015 2:56 PM EDT

Consumer Reports is out negative on the potential deal between Mylan (Nasdaq: MYL) and Teva Pharma (NYSE: TEVA).

In part, the report notes that the deal could hand consumers higher prices for generic and specialty drugs.

Teva and Mylan are both trading at or near session lows on Friday.

... More

Teva Pharma (TEVA) Comments on Stichting's Move to Exercise Call Option on Mylan (MYL); Sees as 'Unwarranted'

July 23, 2015 9:06 AM EDT

Teva Pharma (NYSE: TEVA) issued the following statement regarding Stichting Preferred Shares Mylans (Nasdaq: MYL) decision to exercise its call option:

We strongly disagree with the stated analysis of Stichting Preferred Shares Mylan and its decision... More